Protein Kinase C enzyme “PKC”
Focused on one goal: Developing Novel Therapeutics to tame Cancer
Robert C. McInnis, President & Chief Executive Officer
Bob joined PharmaGap in December 2004. Prior to this, Bob was the Director of Financial Programs at World Heart Corporation, dealing with various financial structuring programs including responsibility for U.S. and Canadian capital markets regulatory affairs. Previously, Bob was president of SC Stormont Corporation and was involved in the corporate financial management for the Ottawa Senators Hockey Club and The Corel Centre. Before that, Bob was employed at SHL Systemhouse Inc., at the time, Canada’s largest computer system integration company where he held a number of key financial management roles including corporate structuring, and mergers and acquisitions activity. Bob is a chartered accountant and holds a Bachelor of Mathematics degree from the University of Waterloo.
Roderick M. (Rod) Bryden, Chairman of the Board
Mr. Bryden is Chairman of PharmaGap and the founder and Chairman of SC Stormont Inc., a business advisory company which participates in the development of small to mid-sized Canadian businesses. He is also the President of Plasco Energy Group and a director of Clearford Industries. He was the former Chairman and CEO of WorldHeart Corporation, Paperboard Industries, Systemhouse Ltd. and was the CEO of Terrace Corporation, the principal owner of the Ottawa Senators NHL hockey franchise. Mr. Bryden has taught law at the University of Saskatchewan and was a senior federal government official. He has a B.A. (Hon. Economics) from Mount Allison University (New Brunswick), LLB from the University of New Brunswick and LLM from the University of Michigan, Ann Arbor.
Daniel Larkin, Director
Mr. Larkin holds an MBA, with concentration in finance, from York University and has 30 years experience in all business functions, including senior management with Imperial Oil Ltd. (25 years), and in the high tech industry. He has been CEO of two small public companies including Sebring Resources Ltd. (1997-2002), the predecessor Company to PharmaGap and was the CFO of PharmaGap (2002-2003).
Michel Phipps, Ph.D., Director
Co-founder of PharmaGap.
Dr.Phipps specializes in mathematical modeling of physical phenomena. Dr. Phipps taught at the University of Ottawa and is currently Professor Emeritus. He has collaborated with Dr. Jenny Phipps, CSO, on cell communication and has spent two sabbaticals at the National Research Council of Canada studying cell communication and modeling its activity. Dr. Phipps received a doctorat d'état (state doctorate) in France.
Robert Letellier, Director
President of Ab Biotech Inc. Co-founder and former President & CEO of PharmaGap(1999-2004).
Prior to founding PharmaGap, Mr. Letellier was with the National Research Council of Canada and Industry Canada in Ottawa advising emerging technology companies on commercialization strategies. Mr. Letellier has a B.A. (Economics) from the University of Sherbrooke.
Jenny Phipps, Ph.D., Chief Scientific Officer, Director
Simon Goulet, Executive Vice President & Chief Operating Officer
Simon joined PharmaGap in December 2003 as Chief Financial Officer and was appointed to his new position in December 2004. Previously, he was Vice President, Investment Banking with Credit Suisse First Boston in New York and TD Securities in New York and Toronto, where he was responsible for numerous assignments raising capital and executing M&A transactions. He is also a co-founder of a company in Greenwich, Connecticut licencing financial software and he has sold medical products to hospitals and clinics for Kodak Canada Inc. Simon has a B.Sc. (Biochemistry) from Queen’s University and an MBA from the University of Western Ontario.
David Barnes, M.D., Clinical Development & Regulatory Affairs Consultant
David has been working with PharmaGap since January 2004 and is responsible for all aspects of the Company’s clinical testing efforts and regulatory affairs. He is the co-founder and Managing Partner of BioTheragene Clinical Research Consultants and the Chalmers Research Group, both well regarded clinical study consultancies based in Ottawa. Previously David was Head of the Biotechnology Drug Evaluation Unit at Health Canada and he was a practicing family physician. David has 10 years experience in molecular biology and clinical research and is former Investigator at the University of Ottawa’s Evidence Based Practice Center. He has been a contract drug development executive for pharmaceutical companies since 2001. David is an M.D., Memorial University of Newfoundland.
Jenny Phipps, Ph.D., Chief Scientific Officer, Director
Co-founder of PharmaGap. Jenny is an experienced molecular biologist with a strong interest in signal transduction processes and their effect on disease. As CSO, Jenny designed and implemented the core drug development program targeting PKC. Before joining the Company full-time in 2001, Jenny was a senior researcher at the National Research Council of Canada in Ottawa, an adjunct professor at the University of Ottawa (School of Medicine) and an assistant professor of biology at Carleton University (Ottawa). She has a Doctorate (Molecular Genetics) from the Universite Paul Sabatier (France).
Jennifer Arnold, Ph.D., Director Pre-Clinical Development
Jennifer joined PharmaGap in 2001 as a post-doctorate fellow, focusing on modulation of protein kinases implicated in cancer, multi-drug resistance and neurological disorders. She has been instrumental in developing the Company’s pre-clinical program and is currently directing animal studies for PharmaGap’s lead drug cancer program. In addition to her work at PharmaGap, Jennifer has been a sessional lecturer for the Biochemistry Department at The University of Ottawa and is an Adjunct Professor at Carleton University (Ottawa). She holds a doctorate in neurosciences from Carleton University, a M.Sc. in Pharmacology from Universite de Sherbrooke (Quebec) and an honours B.A. (Psychology) from Bishop’s University (Quebec).
Gerald Leahy, Chief Financial Officer
Gerald joined Pharmagap as Chief Financial Officer in December, 2004 bringing more than 20 years of industry experience in public and private companies, including 14 years in the high-tech sector. As a financial professional he has successfully developed and managed finance groups throughout the building and growth stages of companies. He has been involved in private and public financings, international expansion into foreign markets as well as reorganizations. Gerald was a key player in Simware Inc.’s Nasdaq IPO and the eventual merger with Netmanage Inc., and also recently acted as CFO during Linmor Inc.’s strategic sale to Nuvo Network Management Inc. Gerald is a CMA and holds a Bachelor of Commerce degree from Carleton University.